Status:
COMPLETED
Magnetic Marker Monitoring (MMM) Study With Gel Matrix Tablets Under Fasting and Fed Conditions
Lead Sponsor:
AstraZeneca
Conditions:
Magnetic Marker Monitoring
Gastrointestinal-transport
Eligibility:
MALE
18-55 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to monitor the gastrointestinal transport of eroding gel matrix placebo tablets in healthy male volunteers under fasting and fed conditions. The method which is used is an...
Eligibility Criteria
Inclusion
- Ethnic origin: Caucasian
- Body-mass index (BMI): ≥ 19 kg/m² and ≤ 27 kg/m²
- Good health
- Written informed consent, after having been informed about benefits and potential risks of the trial
Exclusion
- Diseases which could influence the gastric emptying and gastrointestinal transport
- Diet which could influence the gastric emptying and gastrointestinal transport
- Surgery in the gastrointestinal tract which may interfere with the safety and transport of test product
- Ferromagnetic implants or any other magnetic disturbance, which can affect the Magnetic Marker Monitoring measurement
- Regular medical treatments which could affect the gastric emptying and gastrointestinal transport
Key Trial Info
Start Date :
October 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2010
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT01224587
Start Date
October 1 2010
End Date
November 1 2010
Last Update
November 4 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Berlin, Germany